e-learning
resources
Amsterdam 2015
Wednesday, 30.09.2015
Emerging technologies for malignant pleural diseases management
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Volatile organic compounds increase the likelihood of detecting malignant pleural mesothelioma
Kevin Lamote (Gent, Belgium), Kevin Lamote, Matthijs Vynck, Joris Van Cleemput, Olivier Thas, Kristiaan Nackaerts, Jan P. Van Meerbeeck
Source:
International Congress 2015 – Emerging technologies for malignant pleural diseases management
Session:
Emerging technologies for malignant pleural diseases management
Session type:
Oral Presentation
Number:
5002
Disease area:
Thoracic oncology
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Kevin Lamote (Gent, Belgium), Kevin Lamote, Matthijs Vynck, Joris Van Cleemput, Olivier Thas, Kristiaan Nackaerts, Jan P. Van Meerbeeck. Volatile organic compounds increase the likelihood of detecting malignant pleural mesothelioma. Eur Respir J 2015; 46: Suppl. 59, 5002
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion on Basic translational and clinical research – building a career in paediatric pulmonology- experiences from clinicians in lower middle income countries
ERS/EAACI statement on severe exacerbations in asthma in adults: facts, priorities and key research questions
Definition and history of sarcoidosis
Related content which might interest you:
Volatile organic compounds as an early diagnostic tool for malignant pleural mesothelioma
Source: International Congress 2014 – Diagnosis and treatment of pleural mesothelioma
Year: 2014
A breath test for malignant mesothelioma using an electronic nose
Source: Eur Respir J 2012; 40: 448-454
Year: 2012
Detection of mesothelin in the pleural effusion has a higher diagnostic utility than in serum for diagnostic of malignant mesothelioma
Source: Annual Congress 2013 –Clinical problems in mediastinal and pleural malignacies
Year: 2013
Drug repurposing in malignant pleural mesothelioma: a breath of fresh air?
Source: Eur Respir Rev, 27 (147) 170098; 10.1183/16000617.0098-2017
Year: 2018
Comparison of multiple serum and pleural fluid biomarkers for the diagnosis of Malignant Pleural Mesothelioma
Source: International Congress 2017 – Mesothelioma and malignant pleural disease
Year: 2017
Exhaled breath analysis allows exclusive screening for malignant pleural mesothelioma.
Source: International Congress 2017 – Mesothelioma and malignant pleural disease
Year: 2017
Breath analysis allows to predict treatment response in malignant pleural mesothelioma patients.
Source: Virtual Congress 2021 – Novel insights into the diagnosis, mechanism and treatment of malignant pleural disease
Year: 2021
Comparison between mesothelin and fibulin-3 detection in pleural malignant mesothelioma (MPM) patients
Source: International Congress 2016 – Mesothelioma and malignant pleural disease
Year: 2016
Detection of EpCAM-positive microparticles in pleural fluid: A new approach for the diagnosis of the tumoral origin of pleural effusions
Source: International Congress 2015 – Emerging technologies for malignant pleural diseases management
Year: 2015
Diagnostic value of pleural fluid angiopoietin-2 (Ang-2) levels, to differentiate malignant pleural effusions from benign pleural effusions
Source: International Congress 2016 – Mesothelioma and malignant pleural disease
Year: 2016
Volume quantification of malignant pleural mesothelioma
Source: International Congress 2015 – Malignant pleural effusions and mesothelioma
Year: 2015
Role of Dr-70 immunoassay in suspected malignant pleural effusion
Source: Annual Congress 2013 –New methods for diagnostic workup of lung cancer
Year: 2013
Exhaled breath to screen for malignant pleural mesothelioma: a validation study
Source: Eur Respir J, 50 (6) 1700919; 10.1183/13993003.00919-2017
Year: 2017
Volatile organic compounds in exhaled breath of patients with COPD ± lung cancer and their correlation with FEV1-values
Source: International Congress 2014 – The assessment of comorbidities
Year: 2014
Biological markers of successful pleurodesis for malignant pleural effusion
Source: International Congress 2016 – Mesothelioma and pleural disease: from the bench to the bedside
Year: 2016
Volatile organic compounds in COPD: Is hexanal an inflammation biomarker?
Source: International Congress 2016 – The future of lung function is beginning now
Year: 2016
Ideal volume sampling in the diagnosis of malignant pleural effusions. Just how much is really enough?
Source: Annual Congress 2013 –Progress in bronchoscopy and pathology techniques for diagnosis of thoracic malignancies
Year: 2013
Differences in volatile organic compounds (VOC) determined in exhaled breath in two populations of lung cancer (LC): With and without COPD
Source: Annual Congress 2013 –New methods for diagnostic workup of lung cancer
Year: 2013
Novel Synthetic lignan reduces asbestos-induced damage in human pleural mesothelial cells-Potential clinical usefulness in inhibiting pleural malignant mesothelioma
Source: International Congress 2017 – Mesothelioma and malignant pleural disease
Year: 2017
Chemical characterization of exhaled breath to discriminate patients with malignant pleural mesothelioma from subjects with similar professional asbestos exposure
Source: Annual Congress 2010 - Clinical diagnosis and management of malignant pleural effusions
Year: 2010
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept